Palisade Bio drops after early-stage trial data for lead asset
Source: SeekingAlpha
2026-03-31 13:10:00 ET
More on Palisade Bio
- Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating
- Seeking Alpha’s Quant Rating on Palisade Bio
- Historical earnings data for Palisade Bio
- Financial information for Palisade Bio
Read the full article on Seeking Alpha
For further details see:
Palisade Bio drops after early-stage trial data for lead asset
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
1.02% G/L:
$212.64 Last:
1,382,100 Volume:
$209.48 Open:
ABBV Latest News
April 08, 2026 12:33:51 pm
Anthropic Inks US$400 Million Deal for AI Biotech Startup Coefficient Bio
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
